ArriVent Corp - AVBP Net earnings per share for the last 12 months

Public company logo of ArriVent Corp (AVBP)

ArriVent BioPharma, Inc (AVBP) management focuses on developing targeted therapies to combat lung oncology. The YoY EPS volatility over the last 12 months illustrates profit dynamics, where 13.60 reflects the metric's baseline. The company relies on a precision approach to EGFR mutations, utilizing Chinese R&D platforms. Development is based on the targeted licensing of innovative molecules without pursuing mergers.

ArriVent BioPharma (AVBP): Earnings per share for the last twelve months from 11/23/2025 to 11/17/2026

AVBP (ArriVent BioPharma, Inc): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Initial company analysis:ArriVent BioPharma, Inc. AVBP
Mass-produced product of ArriVent Corp

Fundamental asset screening requires an analysis of the rate of change in net earnings per share over a twelve-month period. The rolling annual EPS YoY trend measures the growth rate of business profitability, which is critical for ArriVent BioPharma, Inc (AVBP) until the commercialization of targeted therapy and the commencement of bulk drug procurement by oncology centers and insurance companies.